CRISIL has downgraded Trident Texofab's bank facilities rating to 'CRISIL B/Stable' reflecting liquidity challenges and financial pressure. The company saw a decline in revenue and profit in FY26.
Trident Texofab Credit Rating Downgraded by CRISIL
CRISIL Ratings has downgraded the credit rating for Trident Texofab Limited's bank facilities to 'CRISIL B/Stable' from 'CRISIL B+/Stable'. This action highlights ongoing liquidity challenges and financial pressure faced by the company. ## What just happened CRISIL has downgraded Trident Texofab's bank facilities amounting to ₹20 crore. The downgrade signals increased financial risk for the company. ## Why this matters This downgrade makes it potentially more expensive for Trident Texofab to access credit and reflects investor concerns about its financial health and ability to meet obligations. ## The backstory For the fiscal year 2026, Trident Texofab reported a decline in operating income to ₹118 crore from ₹122.19 crore in FY2025. Profit after tax (PAT) also fell to ₹0.7 crore from ₹2.51 crore, with the PAT margin contracting to 0.6% from 2.05%. The interest coverage ratio improved to 1.51 times from 1.16 times. ## What changes now The company's creditworthiness has been reassessed downwards, which could impact its borrowing costs and relationships with financial institutions. The rating reflects a stretched liquidity position, with high utilization of bank limits (87% for the year ending May 2026) and insufficient net cash accrual against debt obligations. ## Risks to watch Key risks include persistent liquidity issues, operational sensitivity to raw material price fluctuations, intense competition, a stretched working capital cycle (277 days as of March 31, 2026), and continued reliance on promoter funding. ## Peer comparison The textile industry is fragmented, with companies facing volatility in raw material costs like cotton and yarn. Margin stability is a challenge for most players in this competitive landscape. ## Context metrics (time-bound) As of March 31, 2026, net cash accrual was ₹2.3 crore. Bank limit utilization averaged 87% for the 12 months ending May 2026. The company managed its working capital cycle over 277 days as of March 31, 2026. ## What to track next Investors should monitor Trident Texofab's efforts to improve revenue, stabilize operating margins, enhance cash generation, and manage its working capital cycle. Promoter support remains crucial for sustained operations.
Disclaimer:This article is published for informational purposes only. While reasonable efforts are made to ensure accuracy, completeness, and timeliness, readers are encouraged to independently verify information before making any decisions based on the content. The views and information presented are subject to editorial review and may be updated without notice.
